RecruitingNot applicableNCT07187297
Connective Tissue
Cutis Laxa
Also known as elastolysis, generalized elastolysis, loose skin syndrome
Cutis laxa encompasses a heterogeneous group of disorders characterised by loose, inelastic, redundant skin caused by deficient or fragmented elastic fibres in dermal and visceral connective tissue. Genetic forms range from isolated skin in
ORPHA:209 ↗Gene ELNGene ATP7AGene ATP6AP2 (multiple)Prevalence Fewer than 1 in 1,000,000 (severe congenital forms)Onset Congenital or early childhood (most genetic forms); adulthood (acquired)Genetic (multiple inheritance patterns) or acquired
16
studies recruiting now
as of 7 Sept 2026
188
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
9 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07614997
Effectiveness and Safety of the Ulthera® System for Skin Laxity in the Lower Face, Submentum and Neck
RecruitingNot applicableNCT07637188
PLLA-LASYNPRO™ Injections for Skin Laxity Treatment
RecruitingNot applicableNCT05750901
Evaluation of Fractional Ablative Laser Treatment for Skin Conditions
RecruitingNot applicableNCT07229430
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 16 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Cutis Laxa study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Cutis Laxa
Cutis laxa encompasses a heterogeneous group of disorders characterised by loose, inelastic, redundant skin caused by deficient or fragmented elastic fibres in dermal and visceral connective tissue. Genetic forms range from isolated skin involvement to severe systemic disease affecting the lungs (emphysema), cardiovascular system, and skeleton, while acquired forms typically follow an inflammatory trigger. The specific gene affected determines the inheritance pattern, organ involvement, and prognosis.
Common clinical features
Loose, pendulous, inelastic skin with premature aged appearanceEarly-onset pulmonary emphysema and respiratory insufficiencyVascular abnormalities including aortic aneurysm and tortuosityInguinal, umbilical, or diaphragmatic herniasBladder and bowel diverticulaDevelopmental delay and intellectual disability (in syndromic forms)Skeletal dysplasia and joint laxity
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Cutis Laxa. Not eligibility rules; those are set by each study.
- Genetic subtype must be confirmed prior to enrolment, as trials are frequently gene-specific (e.g. ELN haploinsufficiency vs. ATP7A-related vs. LTBP4-related forms).
- Pulmonary function testing (spirometry, DLCO) and chest CT are standard baseline assessments for trials targeting systemic cutis laxa with emphysema.
- For paediatric enrolment, developmental milestone records and neuroimaging may be required, particularly for ATP6AP2 and other syndromic subtypes.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).